Pfizer, 23andMe team up to study bowel disease

August 12, 2014

Pfizer Inc. is teaming up with DNA testing company 23andMe to study the possible genetic underpinnings of inflammatory bowel disease, a hard-to-treat ailment that affects an estimated 1.4 million Americans.

Under the partnership, 23andMe will map the DNA of 10,000 patients who have forms of the disease, which include Crohn's disease and ulcerative colitis. Patients will submit saliva samples using 23andMe's at-home collection kit and then fill out online questionnaires about their disease and symptoms.

The companies say they hope to identify genetic similarities among patients with , which could guide development of targeted drugs to treat the disease.

The cause of is unknown, though many scientists suspect genetics play a role. Other scientists believe the diseases are triggered by a virus or bacteria.

Explore further: Reproductive disorder linked to increased risk of inflammatory bowel disease

Related Stories

Inflammatory bowel disease raises risk of melanoma

May 20, 2013

Patients with inflammatory bowel disease (IBD) are at higher risk of melanoma, a form of skin cancer, report researchers at Mayo Clinic. Researchers found that IBD is associated with a 37 percent greater risk for the disease. ...

Recommended for you

New method provides better information on gene expression

July 1, 2016

Scientists at Karolinska Institutet and the Royal Institute of Technology (KTH) have devised a new high-resolution method for studying which genes are active in a tissue. The method can be used on all types of tissue and ...

Indicator of chronic fatigue syndrome found in gut bacteria

June 27, 2016

Physicians have been mystified by chronic fatigue syndrome, a condition where normal exertion leads to debilitating fatigue that isn't alleviated by rest. There are no known triggers, and diagnosis requires lengthy tests ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.